Table 3.

Treatment duration and OR according to classifications of the investigational agents

Treatment duration, days	Total	Infection (−)	Infection (+)	Grade ≥3 infection (−)	Grade ≥3 infection (+)
Overall	n=641	n=509	n=132	n=595	n=46
Mean (SD)	120.4 (194.5)	109.1 (170.9)	163.8 (263.1)	124.1 (198.9)	72 (115.1)
Median (IQR)	54 (29–126)	50 (29–121)	63.5 (30.8–173)	57 (29–128)	34 (21–68)
Range	4–1659	4–1659	4–1547	4–1659	4–686
P value		0.09		<0.001
CTA	n=35	n=24	n=11	n=27	n=8
Mean (SD)	53.8 (50.9)	65.5 (56.3)	28.4 (22.2)	63.1 (54.6)	22.5 (9.20)
Median (IQR)	22 (21–84.5)	38.5 (21–121)	21 (20.5–26.5)	38 (21–106)	21 (20–24.3)
Range	8–171	9–171	8–91	9–171	8–39
P value		0.07		0.08
PAM	n=61	n=35	n=26	n=54	n=7
Mean (SD)	98.2 (108.7)	73.6 (82.7)	131.2 (130.7)	102.1 (113.3)	68.1 (59.8)
Median (IQR)	62 (30–121)	32 (30–87.5)	98 (49–170.8)	62.5 (30.3–121)	41 (27.5–98)
Range	9–665	15–398	9–665	15–665	9–176
P value		0.004		0.49
MTA	n=445	n=368	n=77	n=419	n=26
Mean (SD)	114.2 (182.2)	107.1 (167.6)	148.1 (238.5)	116.3 (184.4)	81.5 (141.0)
Median (IQR)	46 (28–122)	44 (28–119.5)	56 (30–131)	50 (28.5–128)	34.5 (21.3–67)
Range	4–1536	4–1339	4–1536	4–1536	4–686
P value		0.36		0.04
ICI	n=100	n=82	n=18	n=95	n=5
Mean (SD)	184.5 (285.5)	145.9 (222.8)	360.3 (445.2)	188.5 (291.5)	107.2 (110.7)
Median (IQR)	84.5 (44–196)	84 (43.3–153.8)	200 (56.5–371.5)	85 (44.5–201)	56 (36–119)
Range	9–1659	9–1659	30–1547	9–1659	30–295
P value		0.04		0.62
Positive rate			0.206		0.072
CTA			0.314		0.229
PAM			0.426		0.115
MTA			0.173		0.058
ICI			0.180		0.050
OR
CTA vs MTA		2.19 (1.03–4.66), p=0.04		4.78 (1.98–11.5), p<0.001
PAM vs MTA		3.55 (2.02–6.24), p<0.001		2.09 (0.87–5.04), p=0.10
ICI vs MTA		1.05 (0.60–1.85), p=0.87		0.85 (0.32–2.27), p=0.74

Treatment duration with infection-related adverse events and without were compared by Mann-Whitney U test.

CTA, cytotoxic agent; ICI, immune checkpoint inhibitor; MTA, molecular targeted agent; PAM, PI3K-AKT-mTOR.